Not independent
Tenure on this board
2.7 yrs
6 nominees · 9 ballot items.
The meeting will consider nine management-proposed proposals: name change to ZeroStack, creation of a new class of preferred shares, amendments to the 2022 Plan, grants of stock options to top executives, PIPE and convertible notes issuances, a forward share split, and the option to adjourn the meeting.
Approve the amendment to change the Company's name from Flora Growth Corp. to 'ZeroStack Corp.' or another Board-determined name, via Articles amendment.
Approve an amendment to authorize an unlimited number of preferred shares, issuable in series with rights, privileges and conditions to be set by the Board, as a class with the Common Shares.
Approve amendments to the 2022 Incentive Compensation Plan to increase the number of Common Shares issuable to 10% of fully diluted shares and increase the Incentive Stock Options under the plan to the lower of 2,000,000 or the number of shares issued and outstanding at approval.
Approve the grant of stock options to the Chief Executive Officer, Chief Financial Officer and Executive Chairman as described, subject to shareholder approval.
Approve for Nasdaq compliance the issuance of Common Shares underlying pre-funded warrants and warrants sold in the September 2025 Private Placement, to certain investors.
Approve for Nasdaq compliance the issuance of Common Shares underlying the DeFi convertible note, subject to conversion terms and cap, including potential issuance of DeFi Note Shares upon conversion.
Approve for Nasdaq compliance the issuance of Common Shares underlying the Zero Gravity convertible note, subject to conversion terms and the Maximum Percentage restrictions, including potential issuance of Zero Gravity Note Shares.
Approve the forward share split of the Company's outstanding Common Shares in a ratio from 2:1 to 10:1, with Board discretion to fix the ratio and timing within one year.
Authorize adjournment or postponement of the Meeting to permit further solicitation of proxies if needed to approve Proposals 1-8.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.05% | 25,440 | $157K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.89% | 21,656 | $134K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 0.52% | 12,648 | $78K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 0.15% | 3,665 | $23K |
| 5 | UBS Group AG | 0.03% | 665 | $4K |
| 6 | MORGAN STANLEY | 0.01% | 168 | $1K |
| 7 | Sound Income Strategies, LLC | 0.00% | 12 | $72 |
| 8 | ROYAL BANK OF CANADA | 0.00% | 12 | $74 |
| 9 | Bernard Wealth Management Corp. | 0.00% | 12 | $75 |
| 10 | OSAIC HOLDINGS, INC. | 0.00% | 10 | $61 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.